Involvement of everolimus‑induced ABCB1 downregulation in drug‑drug interactions
- PMID: 39420918
- PMCID: PMC11484175
- DOI: 10.3892/br.2024.1872
Involvement of everolimus‑induced ABCB1 downregulation in drug‑drug interactions
Abstract
Everolimus is an oral mammalian target of rapamycin (mTOR) inhibitor used in cancer chemotherapy and transplantation. Due to its therapeutic properties, everolimus has been used long-term in clinical practice. Drug interactions with everolimus during gastrointestinal absorption can alter the oral bioavailability of everolimus and/or concomitant drugs. However, the effects of everolimus on gastrointestinal absorption remain unknown. The present study assessed the impact of continuous exposure to everolimus on expression and function of the ATP-binding cassette (ABC) transporter ABCB1 and ABCG2 using a Caco-2 intestinal cell model. Caco-2 subline, Caco/EV, was established by continuously exposing Caco-2 cells to 1 µM everolimus. Cell viability was evaluated using WST-1 assay. mRNA levels were measured by reverse transcription-quantitative PCR. Transport activity of ABCB1 was evaluated through the cellular accumulation of Rhodamin 123, a substrate for ABCB1. The half-maximal inhibitory concentration (IC50) values for everolimus in Caco-2 and Caco/EV cells were 0.31 and 4.33 µM, respectively, indicating 14-fold resistance in Caco/EV cells. Sensitivity to paclitaxel and 7-ethyl-10-hydroxycamptothecin, which are substrates for ABCB1 and ABCG2, respectively, was enhanced in Caco/EV, but not in Caco-2 cells. The IC50 values of cisplatin were comparable in both cell lines. Furthermore, mRNA expression levels of ABCB1 and ABCG2 were lower in Caco/EV cells than in Caco-2 cells, and the cellular accumulation of Rhodamine 123 was significantly higher in Caco/EV cells. These findings demonstrated that continuous exposure to everolimus suppressed the expression and function of ABCB1 and ABCG2, suggesting potential drug-drug interactions via the suppression of ABCB1 and ABCG2 in the intestinal tract.
Keywords: ABCB1; Caco-2 cell; downregulation; drug interaction; everolimus; transporter.
Copyright: © 2024 Nakayama et al.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures



Similar articles
-
Down-regulation of ABCB1 in Everolimus-resistant Renal Cell Carcinoma Cells.Anticancer Res. 2024 Jul;44(7):2871-2876. doi: 10.21873/anticanres.17099. Anticancer Res. 2024. PMID: 38925842
-
The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.PLoS One. 2013 Aug 14;8(8):e71266. doi: 10.1371/journal.pone.0071266. eCollection 2013. PLoS One. 2013. PMID: 23967177 Free PMC article.
-
Interaction of Phytocompounds of Echinacea purpurea with ABCB1 and ABCG2 Efflux Transporters.Mol Pharm. 2021 Apr 5;18(4):1622-1633. doi: 10.1021/acs.molpharmaceut.0c01075. Epub 2021 Mar 17. Mol Pharm. 2021. PMID: 33730506
-
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.Cancer Res. 2007 Nov 15;67(22):11012-20. doi: 10.1158/0008-5472.CAN-07-2686. Cancer Res. 2007. PMID: 18006847
-
Lipid regulation of the ABCB1 and ABCG2 multidrug transporters.Adv Cancer Res. 2015;125:97-137. doi: 10.1016/bs.acr.2014.10.004. Epub 2015 Jan 8. Adv Cancer Res. 2015. PMID: 25640268 Review.
References
LinkOut - more resources
Full Text Sources
Miscellaneous